BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 16777686)

  • 1. Post-chemotherapeutic administration of interleukin-12 retards tumor growth and enhances immune cell function: combination therapy using paclitaxel and IL-12.
    Pressley JS; Elgert KD
    Cancer Invest; 2006; 24(4):351-9. PubMed ID: 16777686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation.
    Mullins DW; Koci MD; Burger CJ; Elgert KD
    Immunopharmacol Immunotoxicol; 1998 Nov; 20(4):473-92. PubMed ID: 9805229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide.
    Mullins DW; Burger CJ; Elgert KD
    J Immunol; 1999 Jun; 162(11):6811-8. PubMed ID: 10352302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of antitumor effects of paclitaxel (taxol) in combination with red ginseng acidic polysaccharide (RGAP).
    Shin HJ; Kim YS; Kwak YS; Song YB; Kim YS; Park JD
    Planta Med; 2004 Nov; 70(11):1033-8. PubMed ID: 15549658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor cell-derived TGF-beta and IL-10 dysregulate paclitaxel-induced macrophage activation.
    Mullins DW; Martins RS; Burger CJ; Elgert KD
    J Leukoc Biol; 2001 Jan; 69(1):129-37. PubMed ID: 11200057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.
    Bracci L; Moschella F; Sestili P; La Sorsa V; Valentini M; Canini I; Baccarini S; Maccari S; Ramoni C; Belardelli F; Proietti E
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):644-53. PubMed ID: 17255288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aerosol delivery of liposomal formulated paclitaxel and vitamin E analog reduces murine mammary tumor burden and metastases.
    Latimer P; Menchaca M; Snyder RM; Yu W; Gilbert BE; Sanders BG; Kline K
    Exp Biol Med (Maywood); 2009 Oct; 234(10):1244-52. PubMed ID: 19657067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profile of cytokines produced in tumor tissue after administration of cyclophosphamide in a combination therapy with tumor necrosis factor.
    Takiguchi K; Nakamoto T; Inagawa H; Kohchi C; Nishizawa T; Nagasue N; Soma G
    Anticancer Res; 2004; 24(3a):1823-8. PubMed ID: 15274362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10.
    Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA; Abdulsamad K; Adams SL
    Immunol Invest; 2008; 37(4):315-38. PubMed ID: 18569073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines.
    Khatri A; Husaini Y; Ow K; Chapman J; Russell PJ
    Clin Cancer Res; 2009 Apr; 15(7):2323-34. PubMed ID: 19318483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxol-mediated changes in fibrosarcoma-induced immune cell function: modulation of antitumor activities.
    Mullins DW; Walker TM; Burger CJ; Elgert KD
    Cancer Immunol Immunother; 1997 Oct; 45(1):20-8. PubMed ID: 9353423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
    Patil Y; Sadhukha T; Ma L; Panyam J
    J Control Release; 2009 May; 136(1):21-9. PubMed ID: 19331851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy.
    Jung U; Foley JE; Erdmann AA; Toda Y; Borenstein T; Mariotti J; Fowler DH
    Biol Blood Marrow Transplant; 2006 Sep; 12(9):905-18. PubMed ID: 16920556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor mechanism of intratumoral injection with IL-12-expressing adenoviral vector against IL-12-unresponsive tumor.
    Kanagawa N; Gao JQ; Motomura Y; Yanagawa T; Mukai Y; Yoshioka Y; Okada N; Nakagawa S
    Biochem Biophys Res Commun; 2008 Aug; 372(4):821-5. PubMed ID: 18519033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethanol consumption modifies dendritic cell antigen presentation in mice.
    Heinz R; Waltenbaugh C
    Alcohol Clin Exp Res; 2007 Oct; 31(10):1759-71. PubMed ID: 17850646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer.
    Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA; Abulsamad K; Adams SL
    Clin Immunol; 2008 Aug; 128(2):205-18. PubMed ID: 18511346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity.
    Balkow S; Loser K; Krummen M; Higuchi T; Rothoeft T; Apelt J; Tuettenberg A; Weishaupt C; Beissert S; Grabbe S
    Exp Dermatol; 2009 Jan; 18(1):78-87. PubMed ID: 19054060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic immune response induced by intratumoral expression of the fusogenic membrane protein of vesicular stomatitis virus and cytokines encoded by adenoviral vectors.
    Hoffmann D; Bayer W; Wildner O
    Int J Mol Med; 2007 Nov; 20(5):673-81. PubMed ID: 17912460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo activated OVA specific and non-specific CD4+CD25+ regulatory T cells exhibit comparable suppression to OVA mediated T cell responses.
    Li J; Bracht M; Shang X; Radewonuk J; Emmell E; Griswold DE; Li L
    Cell Immunol; 2006 Jun; 241(2):75-84. PubMed ID: 17010326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.